Greater Weight Loss, More Side Effects: What GLP-1 RAs Mean for Women
Key Takeaways:
- Real-world studies show women treated with GLP-1 receptor agonists (GLP-1 RAs) report side effects such as headache, vomiting and dizziness more often than men, even though placebo-controlled trials suggest similar rates in both sexes.
- Women tend to lose more weight on GLP-1 RAs than men, while improvements in blood sugar control are comparable, possibly due to higher drug exposure, stronger suppression of food-motivated behaviours and interactions between GLP-1 signalling and oestrogen.
- The authors call for mandatory sex- and ethnicity-stratified trial reporting, more research across every stage of women’s lives, and equitable global access to genuine GLP-1 RAs, as nearly 80% of eligible adults live in low- and middle-income countries where access remains minimal.
A call to action on GLP-1 RA use in women
The second of a Series of papers presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (28 September – 2 October), and published in The Lancet Obstetrics, Gynaecology & Women’s Health, examines the wide-ranging issues surrounding GLP-1 RA use in women.
The authors, including Professor Paul Franks of Lund University and Helsingborg Hospital, Helsingborg, Sweden, and Professor Claire Meek of the Leicester Diabetes Research Centre and Leicester NIHR Biomedical Research Centre, Leicester, UK, alongside colleagues, issue a call to action to strengthen the evidence base for GLP-1 RA use in women worldwide.
The global burden of obesity among women
The prevalence of obesity is estimated to be slightly higher among women than among men, and this difference varies according to socioeconomic status. A recent analysis by the Global Burden of Disease group estimated that, in 2021, the global prevalence of overweight or obesity was 46.7% in females and 43.4% in males. Projections for 2050 rise to 60.3% and 57.4%, respectively.
This gender gap is more pronounced in low- and middle-income countries (LMICs), with the largest gaps seen in sub-Saharan Africa and south Asia. By contrast, men in high-income countries can have higher prevalence rates. The trend is likely to continue in the coming decades and is linked to socioeconomic inequalities, highlighting how broader social barriers disproportionately affect women in many regions of the world.
Why women may lose more weight on GLP-1 RAs
Weight loss with GLP-1 RAs is greater in women than in men, yet improvements in blood sugar control are comparable between the sexes. Several mechanisms could explain this greater weight-loss efficacy in women:
- Higher systemic drug exposure has been observed in women, even after adjusting for body mass.
- Women treated with GLP-1 RAs may experience enhanced suppression of food-motivated behaviours and greater inhibition of palatable food intake.
- Pre-clinical studies have highlighted possible interactions between GLP-1 signalling and oestrogen.
Side effects and weight regain
Real-world studies comparing adverse event rates in women and men treated with these medications have found a higher overall frequency of reported side effects among women, including increased rates of headache, vomiting and dizziness. This contrasts with placebo-controlled trials, which suggest similar rates in both sexes. The authors therefore stress that more studies are needed to quantify side-effect profiles in women and to develop strategies to mitigate them.
It is also well established that weight can be regained rapidly after GLP-1 RA treatment is stopped. Regaining fat without regaining additional muscle raises concerns about longer-term health and physical function in women, and further research is needed to ensure these powerful medications support women’s wellbeing over the long term.
Mental health and psychiatric safety
Trial data to date support the overall psychiatric safety profile of GLP-1 RAs, while reinforcing the importance of individualised risk assessment. Careful, routine screening for depression, anxiety and eating disorders is recommended for people of both sexes, both before treatment begins and during follow-up.
For healthcare professionals prescribing or supporting people on these medications, The College of Contemporary Health’s GLP-1RAs in Focus course offers a grounding in GLP-1 receptor agonist therapy, helping clinicians approach treatment decisions, monitoring and patient conversations with confidence.
Affordability and access in low- and middle-income countries
Independent manufacturing estimates suggest that semaglutide, for example, could be produced for less than $1 per month’s supply in oral form and $5 per month as an injection. However, recent analyses across 99 countries indicate that nearly 80% of adults who meet clinical eligibility criteria for GLP-1 RAs live in LMICs, where access remains minimal. In many of these settings, retail prices exceed $90 per month, placing treatment beyond the reach of women who rely on publicly funded care or out-of-pocket payments.
Diverse populations and polyendocrine metabolic ovarian syndrome
The paper explores multiple areas in which GLP-1 RAs affect women’s health, and highlights the need for further research in each. For example, many women with type 2 diabetes in LMICs are lean, and the BMI threshold at which type 2 diabetes begins to develop is often lower than for people of European ancestry. As a result, significant weight loss could have a more pronounced impact on these women.
Polyendocrine metabolic ovarian syndrome (PMOS; formerly polycystic ovary syndrome) affects around 12% of women worldwide, with the highest rates in the eastern Mediterranean region and south-east Asia. Although weight loss leads to various health improvements in women with PMOS, GLP-1 RAs are not generally available or centrally funded for PMOS in most healthcare systems.
Research priorities across women’s lives
The authors conclude that extensive research into GLP-1 RA use in women is needed across a range of domains, including:
- mental health and eating disorders
- contraception, fertility and polyendocrine metabolic ovarian syndrome
- optimising pre-pregnancy health
- preventing complications
- safety during pregnancy and breastfeeding
- optimising health and body composition during menopause
- optimising cardiovascular health and preventing multimorbidity
- frailty and healthy ageing
The authors’ call to action
In their call to action, the authors say:
- “Women face the highest burden of obesity and its related complications, and should have access to high-quality, equitable, multidisciplinary obesity care worldwide”
- “Sex-stratified and ethnicity-stratified reporting of clinical trials related to GLP-1 receptor agonist use should be mandatory to facilitate future meta-analyses”
- “As the main users of GLP-1 receptor agonists and incretin-based therapies, women’s care should be guided by high-quality studies assessing their treatment’s efficacy and safety, specifically in conditions affecting women (eg, before, during, and after pregnancy)”
- “Existing access pathways to GLP-1 receptor agonists disadvantage women – to maximise the treatment’s benefits, companies, health-care funders, research funders, insurers, and policy makers should promote equitable access to high-quality, genuine GLP-1 RAs for women worldwide”
The authors conclude: “Tackling the global challenges in access to GLP-1 receptor agonists provides substantial opportunities to improve women’s health internationally. However, achieving equitable access will require coordinated action to strengthen supply chains, enhance regulatory vigilance against falsified and compounded products, and embrace innovative therapies – such as oral agents – that are stable, scalable, and potentially more affordable…Advancing women-centred obesity care demands targeted research, including trials inclusive of diverse ethnic groups, women of reproductive age, and LMIC populations, alongside women-focused cost-effectiveness and implementation studies.”
CCH insight
As GLP-1 RAs become central to obesity and diabetes care, understanding how they affect different groups, including women at different life stages, is increasingly important for safe, effective prescribing. Build your knowledge with our GLP-1RAs in Focus CPD course.
Explore GLP-1RAs in Focus – Why Drugs Like Ozempic Work →
Source: European Association for the Study of Diabetes
Read More
Obesity May Not Just Drive Breast Cancer – It May Remove a Natural Defence
Key Takeaways:
- Researchers at Huntsman Cancer Institute at the University of Utah have identified a lipid, 9S-HODE, that is produced in far greater quantities by lean fat cells in the breast than by fat cells affected by obesity – and that helps drive cancerous cells towards their own destruction.
- The finding reframes the relationship between obesity and breast cancer: rather than obesity simply adding a harmful influence, it may also remove a protective one that the body would otherwise supply for itself.
- In preclinical mouse models, restoring 9S-HODE levels in fat cells affected by obesity suppressed breast tumour growth, pointing towards a potentially feasible therapeutic route that works with the body’s existing biology.
A shift in how obesity and cancer risk are understood
A research team at Huntsman Cancer Institute at the University of Utah (the U) has found that obesity prevents a biological process that kills cancerous cells, revealing a possible reason why obesity is a risk factor for breast cancer.
The distinction matters. For years, research into obesity and cancer has largely asked what obesity adds to the picture – inflammation, altered hormone signalling, metabolic disruption. This study asks a different question: what does obesity take away?
“We uncovered the role of a molecule that normally appears in lean tissue that restrains breast cancer growth but is less present with obesity. We know obesity is often a driver of breast cancer, and researchers in our field usually consider how obesity is promoting the disease. But we hadn’t really considered that obesity could also be the loss of something that naturally protects us.” – Keren Hilgendorf, PhD, Huntsman Cancer Institute investigator, assistant professor of biochemistry, University of Utah, and senior author of the study
Hilgendorf and first author Meghan Curtin, doctoral candidate in molecular biology at the U, have published the transformative results of their research in the prestigious journal Science.
Why breast tissue is a special case
Breasts are mostly composed of fat, particularly fat cells called adipocytes. These adipocytes are different depending on a person’s weight and can be lean or obese. In obesity, adipocytes are larger than in their lean counterparts. Hilgendorf also says that the two types of adipocytes generate distinctive microenvironments for cancer cells.
That last point is the crux of the work. Adipocytes are not inert padding around the glandular tissue of the breast – they are metabolically active cells that shape the chemical environment in which any developing cancer must survive. Two people can therefore have breast tissue that looks superficially similar but that behaves very differently at a molecular level, depending on the state of the fat cells within it.
Identifying 9S-HODE
In preclinical models, including breast tissues from donors, Hilgendorf and Curtin found that one of those key differences is the production of a lipid, or fatty acid, known as 9S-HODE.
9S-HODE plays an important role in promoting cell death, particularly a kind of cell death called ferroptosis. This is one way the body purges old and damaged cells, including cells that could be cancerous.
Ferroptosis is, in effect, part of the body’s routine quality control. Cells that are damaged or behaving abnormally are cleared before they can cause harm. A tissue environment that supports ferroptosis is therefore a hostile one for early cancerous cells; an environment that does not support it is considerably more permissive.
What the lean and obese microenvironments do differently
“We found that the lean adipocytes produce much more 9S-HODE than obese ones. This means that cancerous cells die more readily in lean tissue,” says Curtin. “By producing more 9S-HODE, our bodies are actively protecting us, under lean circumstances, in a way it cannot with obesity.”
In other words, the protective mechanism is not switched off entirely in people living with obesity – it is diminished. The supply of the lipid that helps push cancerous cells towards ferroptosis falls away, and with it one of the local defences that breast tissue would otherwise mount on its own behalf.
Restoring the lost signal in preclinical models
In their preclinical mouse models, Hilgendorf and Curtin found that increasing the amount of 9S-HODE in obese adipocytes suppressed breast cancer tumour growth. They believe this new understanding could lead to better therapies.
This is the step that moves the work from observation to intervention. Demonstrating that a molecule is absent is one thing; demonstrating that putting it back changes the trajectory of tumour growth is another, and it is what gives the finding its clinical interest.
“From a clinical perspective, this discovery is incredibly empowering. Because 9S-HODE is naturally present in the body but is lost with obesity, we may be able to restore this protection by putting it back,” says Hilgendorf. “That could become a very feasible therapeutic approach to slow breast cancer growth.”
A therapy built on replacing something the body already makes is, in principle, a more tractable proposition than one built on introducing an entirely foreign agent – though that remains a possibility to be tested rather than an established treatment.
Important caveats
Hilgendorf and Curtin recognize that obesity is just one factor that contributes to breast cancer and that the disease can develop for other reasons. They also say that 9S-HODE seems to be primarily produced by fat cells in the breast, though other fat cells throughout the body may have a similar protective function that will require more research.
Two limits are worth holding onto. First, breast cancer is multifactorial, and no single mechanism accounts for an individual’s risk. Second, the 9S-HODE signal appears to be a local one, generated by fat cells within the breast itself – whether adipose tissue elsewhere in the body performs a comparable protective role for other cancers is an open question.
For clinicians who support people living with obesity, findings of this kind reinforce why obesity is increasingly framed as a complex chronic disease with wide-ranging physiological consequences rather than a matter of body weight alone – the understanding that underpins CCH’s CPD short course Obesity Essentials, which examines the biology, drivers and clinical management of obesity across the care pathway.
What comes next
“We believe this shift in the understanding of the roles of lean and obese adipocytes is the start of something. This is just one discovery, and it’s not the end of the road,” says Curtin. “This opened our eyes to new ways to think about science, and hopefully we can harness what our bodies are already doing to make progress against this disease.”
The critical research happening every day at Huntsman Cancer Institute is supported by the National Institutes of Health/National Cancer Institute, including cancer center support grant P30 CA042014, as well as Huntsman Cancer Foundation.
CCH insight
Research like this is changing how obesity is understood at a cellular level – and with it, how healthcare professionals discuss risk, prevention and treatment with the people in their care. CCH’s Obesity Essentials CPD short course gives clinicians a grounded, evidence-based foundation in the science and clinical management of obesity as a chronic disease.
Source: Huntsman Cancer Institute at the University of Utah
Read More
Weight Bias at Work: What New GLP-1 Research Reveals About Women’s Employment Prospects
Key Takeaways:
- Women who were unemployed when they started GLP-1 medications saw their employment rate rise by nearly 27 percentage points over 18 months, according to a 2026 NBER working paper.
- The gains appeared only among women entering the workforce – those already employed saw no rise in pay or promotion, pointing to perception rather than capability.
- The findings echo long-standing evidence on the financial cost of weight bias, from documented pay gaps to hiring professionals’ judgements based on photographs alone.
A new way to measure an old problem
For years, economists have documented what they call the “obesity penalty” – the social and financial disadvantages people can face because of their weight. It has been a difficult phenomenon to measure cleanly, because the factors that shape someone’s body weight also tend to shape their income, health and opportunities.
The rapid uptake of GLP-1 medications has given researchers something closer to a natural experiment. When large numbers of people begin treatment within a short window, and others who want the same treatment have not yet been able to start, it becomes possible to compare two otherwise similar groups and observe what changes.
That is the approach taken in a 2026 working paper published by the National Bureau of Economic Research, in which Harvard economist Rebecca Diamond examined what happened to women’s employment after they began taking GLP-1 medications.
What the researchers did
Diamond looked at survey data from around 15,000 people. She compared women who had started taking GLP-1 medications with similar women who wanted to take them but had not yet started. The two groups were matched on factors including income, race, body mass index and overall health, so that the comparison was not simply between people in very different circumstances to begin with.
The design matters. Because the comparison group consisted of women who also wanted the medications, the study is less vulnerable to the criticism that people who seek treatment are systematically different in motivation from those who do not.
The result that stands out
Among women who were unemployed at the point they began treatment, the employment rate rose by nearly 27 percentage points over the following 18 months, compared with the matched group who had not yet started.
To put that figure in context, it is a larger gap than the difference in employment between American women with a high school diploma and those holding a university degree. In other words, an 18-month change in body weight was associated with a bigger shift in employment than several years of formal education.
The research does not suggest that losing weight made these women more intelligent, more capable or better qualified for work. Nothing about their skills, experience or credentials changed. What the study raises is a different and more uncomfortable question: whether a change in appearance alters how women are perceived by employers.
Changes beyond the workplace
The effects were not confined to employment. The study also found that single women taking GLP-1 medications were nearly 29 percentage points more likely to get married or move in with a partner than similar women who had not started treatment.
Taken together, the employment and partnership findings describe something broader than a labour market effect. They describe a shift in social response.
The financial cost of weight bias
GLP-1 medications have moved quickly into the mainstream. In 2026, 11% of US adults said they were currently taking one to lose weight, up from just 3% in 2024, according to Gallup.
But the question of how weight shapes women’s working lives long predates the current wave of prescribing. Research was already pointing in this direction well before GLP-1 medications entered the cultural conversation.
What hiring professionals saw
A report from Fairygodboss, an employer review site for women, offered a particularly troubling look at how appearance can shape hiring decisions. In one study, hiring professionals were shown images of women with different body types and asked to evaluate them.
The woman pictured at the highest body weight was judged far more harshly than the others. Twenty percent of respondents described her as “lazy”, a label applied less frequently to every other woman pictured. Just 18% said she appeared to have leadership potential, while 21% described her as “unprofessional”.
These are judgements made on the basis of a photograph alone, with no information about experience, qualifications or performance.
Earnings gaps documented long before GLP-1 medications arrived
The pay data tells a similar story. In 2011, the Federal Reserve Bank of St Louis cited research finding that white women living with overweight earned about 4.5% less than white women whose BMI fell within what researchers classified as the normal range. White women living with obesity earned nearly 12% less.
Two caveats are important here. Those figures were specific to white women and do not apply to everyone. They also say nothing about anyone’s value, ability or contribution. What they suggest is that weight-related bias was already showing up in some women’s pay long before GLP-1 medications became widely available.
When appearance pays
The argument that appearance carries an economic premium is not new, and it is sometimes made bluntly. Codie Sanchez, CEO and founder of Contrarian Thinking, has said that women who wear makeup to work earn about 30% more on average than women who do not.
“Pretty privilege is very real,” she said on an episode of The Burnouts Podcast. “And you can either say ‘That’s not fair, so I’m not doing it.’ or you can win.”
Sanchez acknowledged that the advantage is unfair, but argued that women should use it rather than ignore it. “If it’s going to make me more money to paint my face, clown me up,” she said.
Diamond’s findings suggest weight bias may operate along similar lines. The women who benefited most were those seeking to enter the workforce, where first impressions carry disproportionate weight and where an employer’s judgement is formed quickly and on limited information. For women already in a job, whose managers had direct evidence of their performance, the effect disappeared.
Why this matters in clinical practice
For healthcare professionals, findings like these complicate the consultation room. People starting GLP-1 medications may be motivated by clinical goals, social goals, economic goals, or some mixture of all three, and those motivations shape expectations, adherence and how someone responds if treatment is paused or stopped.
Understanding the pharmacology well enough to have that conversation credibly is increasingly part of everyday practice rather than a specialist concern. Building that grounding is the focus of professional training such as the College of Contemporary Health’s GLP-1RAs in Focus – Why Drugs Like Ozempic Work, a CPD-accredited online short course covering GLP-1 physiology and pharmacology for prescribers and non-prescribers alike.
An uncomfortable conclusion
Losing weight does not make a person more intelligent, more capable, harder working or better qualified for a job. But it may change how other people perceive them.
That is precisely what makes Diamond’s findings difficult to sit with. If some women gain access to more opportunities after losing weight while their underlying abilities remain exactly the same, then the economic benefit is not really a benefit at all. It is a measure of how heavily appearance still shapes the way women are perceived and treated – and of how much value has been withheld from them beforehand.
The medication changed the response. It did not change the woman.
CCH insight
Findings like these are a reminder that GLP-1 medications carry social and economic weight as well as clinical effect – and that patients arrive at the consultation with motivations shaped by far more than a treatment target. CCH’s GLP-1RAs in Focus – Why Drugs Like Ozempic Work CPD short course (2 CPD hours, fully online, CPD-accredited) builds the foundation in GLP-1 physiology and pharmacology that healthcare professionals need to explain the science clearly, set realistic expectations and contribute confidently to treatment discussions, whether or not they prescribe.
Read More
Maternal Obesity Before Pregnancy Tied to 64% Higher Childhood Obesity Risk
Key Takeaways:
- Children whose mothers had obesity before pregnancy were 64% more likely to be affected by overweight or obesity by age 3.
- Gaining excess weight during pregnancy – common among about 41% of mothers studied – was linked to a 39% higher risk.
- Maternal weight factors mattered at different stages, and the links varied between Hispanic and non-Hispanic families.
The roots of childhood obesity may begin in the womb
New research led by the George Mason University College of Public Health has found that children whose mothers began pregnancy with obesity were 64% more likely to be affected by overweight or obesity by age 3. Excessive weight gain during pregnancy was associated with a 39% increase in that risk.
“Our findings suggest that childhood obesity risk may not develop in a single, uniform way, but maternal health before and during pregnancy may play a larger role than many people realize,” said study lead author Hua Min, associate professor in the Department of Health Administration and Policy.
Timing appears to matter
Different pregnancy-related weight factors appeared to matter at different stages. Excess weight gain during pregnancy was more closely linked to infant weight, while maternal obesity was more strongly associated with weight later in toddlerhood. Researchers also found that excess weight gain during pregnancy was common, affecting about four in 10 mothers in the study.
A large, ethnically diverse US study
Published in the International Journal of Obesity, the research is among the largest and most ethnically diverse longitudinal studies in the United States to examine how maternal weight may influence obesity risk in early childhood. Researchers tracked nearly 3,000 mother-child pairs, drawing on data from a Northern Virginia birth cohort taking part in the National Institutes of Health’s Environmental influences on Child Health Outcomes (ECHO) Program.
The George Mason research team included Michael S. Bloom of the Department of Global and Community Health, along with Grace Lawrence, Alma Fuller and Kathi C. Huddleston of the School of Nursing.
Why this matters
Childhood obesity remains one of the most pressing health challenges in the United States. The study notes that nearly 90% of children with obesity at age 3 will continue to be affected by overweight or obesity into early adulthood. Those early patterns can carry long-term consequences, increasing the risk of diabetes, cardiovascular disease and other chronic health problems.
Researchers say the findings reinforce the importance of maternal health before and during pregnancy – not just for pregnancy outcomes, but also for a child’s long-term health trajectory. The findings also suggest that obesity risk may develop differently across populations, with patterns varying among demographic groups.
Study details
The findings were based on the First Thousand Days of Life Study, a Northern Virginia birth cohort taking part in the ECHO Program, which examines how early-life experiences affect child health. George Mason was selected as an ECHO research site in 2019.
Researchers enrolled 2,899 mother-child pairs in Northern Virginia between 2012 and 2019, following families from pregnancy through to age 3.
Key findings
The strongest signal came from maternal weight before conception. Children whose mothers had obesity before pregnancy were 64% more likely to be affected by overweight or obesity by age 3, and the risk rose incrementally with weight: for every one-point increase in maternal pre-pregnancy body mass index (BMI), the likelihood of childhood overweight or obesity climbed by about 4%.
Weight gain during pregnancy carried its own, separate risk. Children whose mothers gained excessive weight while pregnant were about 39% more likely to be affected by overweight or obesity by age 3, and roughly 41% of mothers in the study gained more than national guidelines recommend. Notably, the two factors seemed to act at different points in early life: excess weight gain during pregnancy showed stronger links to higher weight in infancy, whereas maternal weight before pregnancy became more strongly associated with higher child weight later in early childhood. The associations also differed between Hispanic and non-Hispanic families, suggesting that obesity risk may develop differently across populations.
Looking ahead
Taken together, the findings point to the period before and during pregnancy as a meaningful window for a child’s long-term health, rather than a single moment or cause. Because the maternal weight factors appeared to matter at different stages, and because the associations varied between demographic groups, the researchers suggest that efforts to understand and address childhood obesity may need to account for how risk builds over time and how it differs across populations.
Source: George Mason University
Read More
New Research Shows Obesity May Reshape How Breast Cancer Spreads
Key Takeaways:
- Obesity may alter how early, non-invasive breast lesions progress into invasive cancer, a University of Oklahoma study suggests.
- In women with obesity, progression was linked to inflammation, immune cell activity, metabolic changes and raised levels of the enzyme SULF2 – not the rapid cell division seen in women without obesity.
- The findings could improve risk prediction for women with DCIS and help reduce overtreatment.
A different route to invasive disease
Obesity may change how early-stage breast cancer becomes invasive, according to a study by University of Oklahoma researchers published in The American Journal of Pathology.
Obesity is already recognised as a risk factor for invasive breast cancer, but researchers have not fully understood how it helps early, non-invasive breast lesions develop into invasive cancer. A clearer picture of this process could strengthen physicians’ ability to predict and treat the disease.
In the study, breast cancers in women without obesity displayed the typical signs of turning invasive, including rapid cell division and an increased ability to invade neighbouring tissue. In women with obesity, however, the researchers identified a different set of biological changes that appeared to help the cancer become invasive.
The cancer environment became more inflamed, with the arrival of immune cells that advanced the growth of the tumour. The tumour cells also appeared better able to survive under stress, and there were changes in cellular metabolism – how the cells use nutrients for energy.
“This could be why women with obesity are at higher risk for invasive breast cancer,” said Bethany Hannafon, Ph.D., co-lead author of the study and an assistant professor in the Department of Obstetrics and Gynecology at the OU College of Medicine. “The changes that the cancer cells are undergoing are allowing them to survive and thrive.”
A cooperative cancer “neighbourhood”
The researchers also found differences in the “neighbourhood” of cells and tissues surrounding the cancer. Epithelial cells, where the tumour originally develops, co-opt other cells around them to create an environment that is even more conducive to cancer growth.
“In women with obesity, there is cooperation between all the cell types, not just the cancer cells, which helps an early pre-cancer to become an invasive breast cancer,” said co-lead author Elizabeth Wellberg, Ph.D., assistant professor in the Department of Pathology at the OU College of Medicine. “That may be an area of future study – can a drug or intervention that targets only one cell type interrupt the whole network of progression toward invasive cancer?”
The role of the enzyme SULF2
The research team additionally discovered higher levels of an enzyme called Sulfatase 2 (SULF2) in the tumour cells of women with obesity, suggesting that it may play an important part in cancer progression. SULF2 will be a further focus of future studies.
Why better DCIS risk prediction matters
Understanding what causes early, non-invasive tumours – known as ductal carcinoma in situ, or DCIS – to become invasive is important because not all women will go on to develop invasive cancer, yet they currently receive the same treatment.
“In women diagnosed with DCIS, about half will later develop invasive ductal carcinoma (IDC) that spreads into surrounding breast tissue. But we currently have no way of determining which women are most at risk. As a result, many women with DCIS receive the same treatments used for IDC, including surgery, radiation and sometimes hormone therapy. Overtreatment is a major concern, but if we had better ways of determining risk, unnecessary treatments could potentially be reduced,” Hannafon said.
While breast cancer survival rates have improved over the past two decades, the number of women diagnosed with invasive breast cancer has not declined – underscoring the need for better ways to predict and prevent disease progression.
A growing public health concern
The rising prevalence of obesity gives the findings added weight.
“Obesity is on the rise – 50% of Americans are expected to be obese by 2030,” said the paper’s first author, Cole Hladik, Ph.D., who worked in Hannafon’s lab while earning his doctorate. “That statistic further highlights the importance of considering a patient’s metabolic health alongside the biology of the tumor itself.”
Read More
Breastfeeding for Three Months or More Linked to Lower Long-Term Weight Gain in Women
Key Takeaways:
- Women who breastfeed for at least three months may gain significantly less weight later in life, with differences observed decades after childbirth.
- The strongest long-term effect is seen in women who had overweight or obesity before pregnancy.
- Breastfeeding appears to influence energy balance, although individual responses vary and support remains essential.
Long-term impact of breastfeeding on weight
Breastfeeding has long been associated with short-term postpartum weight changes, but new research suggests its effects may extend much further. A study conducted by researchers at the University of Oslo indicates that women who breastfeed for at least three months may experience lower weight gain even decades later.
According to the findings, women gained up to 6.5 kilograms less on average later in life if they breastfed for a minimum of three months. This extends the understanding of breastfeeding beyond its immediate postpartum benefits, highlighting its potential role in long-term weight trajectories.
Previous research has largely focused on weight changes in the first one to two years after childbirth. In contrast, this study followed women for up to 50 years after they had stopped breastfeeding, offering a rare insight into lifelong health patterns. The findings are expected to inform further research into maternal cardiovascular risk.
Large-scale study provides robust data
The analysis drew on data from the Women and Health Study, which includes more than 170,000 women in Norway. The results were published in the American Journal of Clinical Nutrition.
This large cohort allowed researchers to examine how breastfeeding duration relates to weight development across different groups of women, while accounting for factors such as education, physical activity, and smoking.
Strongest effect seen in women with overweight
The most pronounced differences were observed among women who had overweight or obesity in early adulthood, prior to pregnancy.
“We compared women in this group who were otherwise similar in terms of education level, physical activity and smoking. We then found that those who breastfed for three to 15 months gained on average up to 6.5 kilos less from young adulthood to middle age, compared with those who breastfed little,” says Thorbjørn Brun Skammelsrud.
Skammelsrud is completing his doctoral research at the Department of Nutrition, Institute of Basic Medical Sciences at the University of Oslo.
More modest differences in women with normal weight
Among women who had a normal weight in early adulthood, the long-term effect of breastfeeding was still present but less pronounced. Those who breastfed for three to 15 months gained up to 3 kilograms less compared with those who breastfed for shorter periods.
For women who had been underweight before pregnancy, breastfeeding appeared to have little influence on long-term weight outcomes.
Biological mechanisms and individual variation
The study also highlights the complex relationship between breastfeeding and energy balance.
“Breastfeeding increases energy expenditure, so in theory breastfeeding should contribute to weight loss. But precisely because energy expenditure increases, some women will also experience increased appetite when they are breastfeeding,” Skammelsrud explains.
This means that while breastfeeding may support weight regulation at a population level, individual experiences can differ significantly.
Implications for public health
The study included women who had children as early as the 1940s, although the association between breastfeeding and lower weight was strongest among those who gave birth after 1980. This group is considered more representative of current maternal behaviours, particularly in terms of diet and breastfeeding practices.
In Norway, national guidance generally recommends partial breastfeeding for one year or longer, provided both mother and infant are comfortable. Breastfeeding rates in Norway are relatively high compared with many other countries.
“This is positive for public health. At the same time, the study shows that some women may need extra follow-up after giving birth, particularly those with overweight or obesity,” Skammelsrud says.
Offering that kind of tailored follow-up draws on a solid grounding in nutrition and weight management – the focus of professional training such as the College of Contemporary Health’s Nutrition & Weight Management Essentials, a CPD-accredited online short course.
Supporting women who choose to breastfeed
The findings reinforce the importance of enabling and supporting breastfeeding where desired.
“In this study, we see that breastfeeding for at least three months has a positive effect on women’s weight later in life. It is therefore important that breastfeeding is facilitated, and that women who wish to breastfeed are offered qualified support,” the researcher says.
Ensuring access to appropriate guidance and support may help maximise both short-term and long-term health outcomes for women.
CCH insight
As this study shows, supporting women’s weight – particularly those with overweight or obesity – calls for a firm grasp of nutrition and energy balance across the life course. CCH’s Nutrition & Weight Management Essentials CPD short course (10 hours, fully online, CPD-accredited) gives healthcare professionals a solid grounding in the fundamentals of nutrition and the practical methods that help patients achieve and sustain a healthier weight.
Explore Nutrition & Weight Management Essentials →
Combination of Hormone Therapy and Tirzepatide Linked to Greater Weight Loss After Menopause, Study Finds
Key Takeaways:
- Postmenopausal women using menopausal hormone therapy alongside tirzepatide lost around 35% more weight than those using tirzepatide alone in an observational study.
- The findings suggest a potential interaction between hormone therapy and GLP-1-based obesity medications, although causality cannot be confirmed.
- Researchers say the results warrant randomised clinical trials to explore mechanisms and broader cardiometabolic effects.
Weight management challenges after menopause
A new study led by researchers at Mayo Clinic suggests that combining menopausal hormone therapy with tirzepatide may be associated with substantially greater weight loss in postmenopausal women. The findings, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, indicate that women receiving hormone therapy lost around 35% more weight while taking tirzepatide compared with those treated with tirzepatide alone.
Tirzepatide is approved by the US Food and Drug Administration for the treatment of overweight and obesity. The study’s authors say the results could expand treatment options for the many women who experience weight gain and related health risks following menopause.
Menopause is associated with accelerated age-related weight gain and a higher likelihood of developing overweight or obesity, both of which are major risk factors for cardiovascular disease, type 2 diabetes, and other long-term conditions. In addition to changes in body weight, the decline in oestrogen levels that occurs during menopause is also linked to physiological changes that may independently increase cardiovascular risk.
“This study provides important insights for developing more effective and personalized strategies for managing cardiometabolic risk in postmenopausal women,” says Regina Castaneda, MD, postdoctoral research fellow at Mayo Clinic and first author of the study.
Hormone therapy and obesity treatments
Menopausal hormone therapy is considered the most effective first-line treatment for common menopausal symptoms, such as hot flashes and night sweats, which affect up to 75% of postmenopausal women. Despite its widespread use, evidence on how hormone therapy may interact with pharmacological obesity treatments remains limited.
Previous research has suggested that postmenopausal women using hormone therapy may experience greater weight loss when treated with semaglutide, another GLP-1-based medication for obesity. However, until now, no studies had specifically examined whether hormone therapy might influence outcomes in people treated with tirzepatide.
To explore this question, Dr Castaneda and colleagues reviewed data from 120 participants with overweight or obesity who had received tirzepatide for weight management for at least 12 months. Outcomes among participants who were also using menopausal hormone therapy were compared with those of participants with similar characteristics who were not receiving hormone therapy.
Findings and limitations
According to the researchers, women using both treatments experienced markedly greater weight loss than those using tirzepatide alone.
“In this observational study, women who used menopausal hormone therapy lost about 35% more weight than women taking tirzepatide alone. Because this was not a randomized trial, we cannot say hormone therapy caused additional weight loss,” says Maria Daniela Hurtado Andrade, MD, PhD, endocrinologist at Mayo Clinic and senior author of the study.
She adds that other factors may partly explain the difference observed between the groups.
“It is possible that women using hormone therapy were already engaged in healthier behaviors, or that menopause symptom relief improved sleep and quality of life, making it easier to stay engaged with dietary and physical activity changes.”
The authors emphasise that, as an observational analysis, the study cannot establish a causal relationship between hormone therapy and enhanced weight loss. Nonetheless, they argue that the size of the observed difference is clinically meaningful.
Possible biological synergy
Dr Castaneda notes that the findings align with emerging preclinical evidence suggesting a biological interaction between oestrogen and GLP-1-based therapies.
“The magnitude of this difference warrants future studies that could help clarify how GLP-1-based obesity medications and menopausal hormone therapy may interact. Interestingly, preclinical data suggest a potential synergy, with estrogen appearing to enhance the appetite-suppressing effects of GLP-1,” she says.
Such a mechanism could help explain why women receiving hormone therapy appeared to derive additional benefit from tirzepatide in this study.
Next steps for research
The research team plans to build on these findings through more rigorous study designs.
“Next, we plan to test these observations in a randomized clinical trial and determine if benefits extend beyond weight loss – specifically, whether hormone therapy also enhances the effects of these medications on cardiometabolic measures,” says Dr Hurtado Andrade. “If confirmed, this work could speed the development and adoption of new, evidence-based strategies to reduce this risk for millions of postmenopausal women navigating this life stage.”
The study was funded by the Mayo Clinic Center for Women’s Health Research. The full publication includes a complete list of authors, disclosures, and funding sources.
CCH insight:
This is an interesting study, but as the authors state, no conclusions can be drawn from the findings. But it does raise many questions about the possible potential synergistic effects of oestrogen and GLP-1 therapy. Establishing whether cardiometabolic benefits of GLP-1 medications are amplified, as well as weight loss, should be a priority.
Read More